Publications

 


  • 615. A Meta-analysis of Individual Participant Data Reveals an Association between Circulating Levels of IGF-I and Prostate Cancer Risk.

    Travis RC, Appleby PN, Martin RM, Holly JM, Albanes D, Black A, Bueno-de-Mesquita HB, Chan JM, Chen C, Chirlaque MD, Cook MB, Deschasaux M, Donovan JL, Ferrucci L, Galan P, Giles GG, Giovannucci EL, Gunter MJ, Habel LA, Hamdy FC, Helzlsouer KJ, Hercberg S, Hoover RN, Janssen JA, Kaaks R, Kubo T, Le Marchand L, Metter EJ, Mikami K, Morris JK, Neal DE, Neuhouser ML, Ozasa K, Palli D, Platz EA, Pollak MN, Price AJ, Roobol MJ, Schaefer C, Schenk JM, Severi G, Stampfer MJ, Stattin P, Tamakoshi A, Tangen CM, Touvier M, Wald NJ, Weiss NS, Ziegler RG, Key TJ, Allen NE; Endogenous Hormones, Nutritional Biomarkers and Prostate Cancer Collaborative Group, 2016

    Journal: Cancer Res
    Reference: Apr 15;76(8):2288-300

  • 614. Disease-specific survival of patients with invasive cribriform and intraductal prostate cancer at diagnostic biopsy.

    Kweldam CF, Kümmerlin IP, Nieboer D, Verhoef EI, Steyerberg EW, van der Kwast TH, Roobol MJ, van Leenders GJ, 2016

    Journal: Mod Pathol
    Reference: Jun;29(6):630-6

  • 613. Where we are with screening and risk prediction for prostate cancer in 2016.

    Roobol MJ, 2016

    Journal: BJU Int
    Reference: Mar;117(3):381

  • 612. Perspective: Enforce the clinical guidelines.

    Roobol M, 2015

    Journal: Nature
    Reference: Dec 17;528(7582):S123

  • 611. Prostate Specific Antigen as a Tumor Marker in Prostate Cancer: Biochemical and Clinical Aspects.

    Salman JW, Schoots IG, Carlsson SV, Jenster G, Roobol MJ, 2015

    Journal: Adv Exp Med Biol
    Reference: 867:93-114

  • 610. Unorganized prostate-specific antigen-based screening for prostate cancer: more harm than benefit. When will we finally start to implement guidelines and risk assessment tools in clinical practice?

    Roobol MJ, 2015

    Journal: Eur Urol
    Reference: Sep;68(3):363-4

  • 609. Do Treatment Differences between Arms Affect the Main Outcome of ERSPC Rotterdam?

    Bokhorst LP, Venderbos LD, Schröder FH, Bangma CH, Steyerberg EW, Roobol MJ, 2015

    Journal: J Urol
    Reference: Aug;194(2):336-42

  • 608. Ethnicity and prostate cancer: the way to solve the screening problem?

    Bokhorst LP, Roobol MJ, 2015

    Journal: BMC Med
    Reference: Aug 4;13:179

  • 607. [Early detection of prostate cancer–recommendations after 13 years of follow-up in the European randomised study].

    Schröder FH, Roobol MJ, Bangma CH, 2015

    Journal: Ned Tijdschr Geneeskd
    Reference: 159:A8677

  • 606. Prostate-specific antigen-based prostate cancer screening: Past and future.

    Alberts AR, Schoots IG, Roobol MJ, 2015

    Journal: Int J Urol
    Reference: Jun;22(6):524-32

  • 605. Digital rectal examination can detect early prostate cancer.

    Roobol MJ, 2015

    Journal: Evid Based Med
    Reference: Jun;20(3):119

  • 604. Active surveillance for low-risk prostate cancer: developments to date.

    Bangma CH, Valdagni R, Carroll PR, van Poppel H, Klotz L, Hugosson J, 2015

    Journal: Eur Urol.
    Reference: Apr;67(4):646-8

  • 604. Correlation between stage shift and differences in mortality in the European Randomized study of Screening for Prostate Cancer (ERSPC).

    Bokhorst LP, Zappa M, Carlsson SV, Kwiatkowski M, Denis L, Paez A, Hugosson J, Moss S, Auvinen A, Roobol MJ, 2016

    Journal: BJU Int
    Reference: Apr 22.

  • 603. Long-term Results of Active Surveillance in the Göteborg Randomized, Population-based Prostate Cancer Screening Trial.

    Godtman RA, Holmberg E, Khatami A, Pihl CG, Stranne J, Hugosson J, 2016

    Journal: Eur Urol
    Reference: Apr 15

  • 602. Screening for Prostate Cancer Starting at Age 50-54 Years. A Population-based Cohort Study.

    Carlsson S, Assel M, Ulmert D, Gerdtsson A, Hugosson J, Vickers A, Lilja H, 2016

    Journal: Eur Urol
    Reference: Apr 12.

  • 601. Number of screening rounds and post-screening prostate cancer incidence: Results from the Finnish section of ERSPC study.

    Pakarainen T, Raitanen J, Talala K, Taari K, Kujala P, Tammela TLJ, Auvinen A, 2016

    Journal: Eur Urol
    Reference: Jun 10

  • 600. Absolute Effect of Prostate Cancer Screening: Balance of Benefits and Harms by Center within the European Randomized Study of Prostate Cancer Screening.

    Auvinen A, Moss SM, Tammela TL, Taari K, Roobol MJ, Schröder FH, Bangma CH, Carlsson S, Aus G, Zappa M, Puliti D, Denis LJ, Nelen V, Kwiatkowski M, Randazzo M, Paez A, Lujan M, Hugosson J, 2016

    Journal: Clin Cancer Res
    Reference: Jan 1;22(1):243-9

  • 599. Prostate cancer and socioeconomic status in the Finnish Randomized Study of Screening for Prostate Cancer.

    Kilpeläinen T, Talala K, Raitanen J, Tammela TLJ, Kujala P, Taari K, Auvinen A, 2016

    Journal: Am J Epidemiol 2016
    Reference: In press

  • 598. Prostate cancer: Is prostatectomy for Gleason score 6 a treatment failure?

    van der Kwast TH, Roobol MJ, 2015

    Journal: Nat Rev Urol.
    Reference: Jan;12(1):10-1

  • 597. Postscreening follow-up of the Finnish Prostate Cancer Screening Trial on putative prostate cancer risk factors: vitamin and mineral use, male pattern baldness, pubertal development and non-steroidal anti-inflammatory drug use.

    Sarre S, Määttänen L, Tammela TL, Auvinen A, Murtola TJ, 2016

    Journal: Scan J Urol
    Reference: 29:1-7

  • 596. Non-steroidal anti-inflammatory drugs and cancer death in the Finnish Prostate Cancer Screening Trial.

    Veitonmäki T, Murtola TJ, Tammela TL, Talala K, Taari K, Auvinen A, 2016

    Journal: PLoS One
    Reference: 11(4):e0153413

  • 595. Sotalol, but not digoxin is associated with decreased prostate cancer risk. A population-based case-control study.

    Kaapu KJ, Ahti J, Tammela TLJ, Auvinen A, Murtola TJ, 2015

    Journal: Int J Cancer
    Reference: 137(5):1187-95

  • 594. Prostate cancer risk among users of digoxin and other antiarrhythmic drugs in the Finnish Prostate Cancer Screening Trial.

    Kaapu KJ, Murtola TJ, Määttänen L, Talala K, Taari K, Tammela TL, Auvinen A, 2016

    Journal: Cancer Causes Control
    Reference: 27(2):157-64.

  • 593. The Finnish prostate cancer screening trial: analyses on the screening failures.

    Kilpeläinen TP, Tammela TL, Malila N, Hakama M, Santti H, Määttänen L, Stenman UH, Kujala P, Auvinen A, 2015

    Journal: Int J Cancer
    Reference: 136(10):2437-43

  • 592. 5-alpha reductase inhibitor use and prostate cancer survival in the Finnish Prostate Cancer Screening Trial.

    Murtola TJ, Karppa EK, Taari K, Talala K, Tammela TL, Auvinen A, 2016

    Journal: Int J Cancer
    Reference: 138(12):2820-8

  • 591. Polymorphisms of Genes Involved in Glucose and Energy Metabolic Pathways and Prostate Cancer: Interplay with Metformin.

    Murtola TJ, Wahlfors T, Haring A, Taari K, Stenman UH, Tammela TL; PRACTICAL Consortium, Schleutker J, Auvinen A, 2015

    Journal: Eur Urol
    Reference: 68(6):1089-97

  • 590. The Effect of Start and Stop Age at Screening on the Risk of Being Diagnosed with Prostate Cancer

    Godtman RA, Carlsson S, Holmberg E, Stranne J, Hugosson J, 2016

    Journal: J Urol
    Reference: May;195(5):1390-6

  • 589. Role of Magnetic Resonance Imaging in Prostate Cancer Screening: A Pilot Study Within the Goteborg Randomised Screening Trial

    Grenabo Bergdahl A, Wilderäng U, Aus G, Carlsson S, Damber J-E, Frånlund M, Geterud K, Khatami A, Socratous A, Stranne J, Hellström M, Hugosson J, 2015

    Journal: Eur Urol
    Reference: Dec 24.

  • 588. A positive family history as a risk factor for prostate cancer in a population-based study with organised prostate-specific antigen screening: results of the Swiss European Randomised Study of Screening for Prostate Cancer (ERSPC, Aarau).

    Randazzo M, Müller A, Carlsson S, Eberli D, Huber A, Grobholz R, Manka L, Mortezavi A, Sulser T, Recker F, Kwiatkowski M., 2015

    Journal: BJU Int.
    Reference: Aug 31.

  • 587. Reducing overdiagnosis by polygenic risk-stratified screening: findings from the Finnish section of the ERSPC.

    Pashayan N, Pharoah PD, Schleutker J, Talala K, Tammela TLj, Määttänen L, Harrington P, Tyrer J, Eeles R, Duffy SW, Auvinen A, 2015

    Journal: Br J Cancer
    Reference: Sep 29;113(7):1086-93

  • 586. Differences among men on active surveillance for very low-risk prostate cancer detected through population-based versus opportunistic prostate-specific antigen-screening.

    Randazzo M, Beatrice J, Huber A, Grobholz R, Manka L, Recker F, Kwiatkowski M, 2015

    Journal: Urol Int.
    Reference: 94(3):330-6.

  • 585. Use of non-steroidal anti-inflammatory drugs and prostate cancer survival in the finnish prostate cancer screening trial.

    Veitonmäki T, Murtola TJ, Määttänen L, Taari K, Stenman UH, Tammela TL, Auvinen A, 2015

    Journal: Prostate
    Reference: Sep;75(13):1394-402

  • 584. Prostate cancer screening using risk stratification based on a multi-state model of genetic variants.

    Yen AM, Auvinen A, Schleutker J, Wu YY, Fann JC, Tammela T, Chen SL, Chiu SY, Chen HH, 2015

    Journal: Prostate
    Reference: Jun;75(8):825-35.

  • 583. Ethnicity and prostate cancer: the way to solve the screening problem?

    Bokhorst LP, Roobol MJ, 2015

    Journal: BMC Med.
    Reference: Aug 4;13:179

  • 582. Early detection of prostate cancer–recommendations after 13 years of follow-up in the European randomised study

    Schröder FH, Roobol MJ, Bangma CH, 2015

    Journal: Ned Tijdschr Geneeskd.
    Reference: 159:A8677.

  • 581. Rule-based versus probabilistic selection for active surveillance using three definitions of insignificant prostate cancer.

    Venderbos LD, Roobol MJ, Bangma CH, van den Bergh RC, Bokhorst LP, Nieboer D, Godtman R, Hugosson J, van der Kwast T, Steyerberg EW, 2016

    Journal: World J Urol.
    Reference: Feb;34(2):253-60

  • 580. Prostate cancer screening in Europe – Authors’ reply.

    Schröder F, Hugosson J, Carlsson S, Moss S, Roobol M, Auvinen A, 2015

    Journal: Lancet
    Reference: Apr 18;385(9977):1507-8

  • 579. Corrigendum to “Incidence of Prostate Cancer After Termination of Screening in a Population-based Randomised Screening Trial” [Eur Urol 2013;64:703-9].

    Bergdahl AG, Holmberg E, Moss S, Hugosson J, 2015

    Journal: Eur Urol
    Reference: Aug;68(2):e46.

  • 578. Metastatic Prostate Cancer Incidence and Prostate-specific Antigen Testing: New Insights from the European Randomized Study of Screening for Prostate Cancer.

    Buzzoni C, Auvinen A, Roobol MJ, Carlsson S, Moss SM, Puliti D, de Koning HJ, Bangma CH, Denis LJ, Kwiatkowski M, Lujan M, Nelen V, Paez A, Randazzo M, Rebillard X, Tammela TL, Villers A, Hugosson J, Schröder FH, Zappa M, 2015

    Journal: Eur Urol.
    Reference: Nov;68(5):885-90

  • 577. Is further screening of men with baseline PSA < 1ng/ml worthwhile? the discussion continues - results of the Swiss ERSPC (Aarau).

    Randazzo M, Beatrice J, Huber A, Grobholz R, Manka L, Chun FK, Kluth LA, Wyler SF, Recker F, Kwiatkowski M, 2015

    Journal: Int J Cancer
    Reference: Aug 1;137(3):553-9.

  • 576. Prostate cancer screening: and yet it moves!

    Kwiatkowski M, Randazzo M, Kluth L, Manka L, Huber A, Recker F, 2015

    Journal: Asian J Androl
    Reference: May-Jun;17(3):437-8.

  • 575. The Finnish prostate cancer screening trial: Analyses on the screening failures.

    Kilpeläinen TP, Tammela TL, Malila N, Hakama M, Santti H, Määttänen L, Stenman UH, Kujala P, Auvinen A, 2015

    Journal: Int J Cancer
    Reference: May 15;136(10):2437-43.

  • 574. Opportunistic Testing Versus Organized Prostate-specific Antigen Screening: Outcome After 18 Years in the Göteborg Randomized Population-based Prostate Cancer Screening Trial.

    Arnsrud Godtman R, Holmberg E, Lilja H, Stranne J, Hugosson J., 2015

    Journal: Eur Urol
    Reference: Sep;68(3):354-60

  • 573. Reply from Authors re: Sigrid V. Carlsson, Peter C. Albertsen. Better Survival After Curative Treatment for Screen-detected Prostate Cancer Compared with Clinical Diagnosis: A Real Effect or Lead-time Bias? Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2014.10.035: Better Treatment in the Control Arm of the ERSPC Rotterdam: A Point Worth Noting?

    Bokhorst LP, Roobol MJ, Kranse R, 2014

    Journal: Eur Urol
    Reference: Nov 20.

  • 572. The added value of percentage of free to total prostate-specific antigen, PCA3, and a kallikrein panel to the ERSPC risk calculator for prostate cancer in prescreened men.

    Vedder MM, de Bekker-Grob EW, Lilja HG, Vickers AJ, van Leenders GJ, Steyerberg EW, Roobol MJ, 2014

    Journal: Eur Urol
    Reference: Dec;66(6):1109-15.

  • 571. Cost-effectiveness of prostate cancer screening: a simulation study based on ERSPC data.

    Heijnsdijk EA, de Carvalho TM, Auvinen A, Zappa M, Nelen V, Kwiatkowski M, Villers A, Páez A, Moss SM, Tammela TL, Recker F, Denis L, Carlsson SV, Wever EM, Bangma CH, Schröder FH, Roobol MJ, Hugosson J, de Koning HJ, 2014

    Journal: J Natl Cancer Inst
    Reference: Dec 13;107(1):366.

  • 570. Differences in Treatment and Outcome After Treatment with Curative Intent in the Screening and Control Arms of the ERSPC Rotterdam.

    Bokhorst LP, Kranse R, Venderbos LD, Salman JW, van Leenders GJ, Schröder FH, Bangma CH, Roobol MJ; for the ERSPC Rotterdam Study Group, 2015

    Journal: Eur Urol
    Reference: Aug;68(2):179-82.

  • 569. Influence of metformin use on PSA values, free‑to‑total PSA, prostate cancer incidence and grade and overall survival in a prospective screening trial (ERSPC Aarau)

    Randazzo M, Beatrice J, Huber A, Grobholz R, Manka L, Wyler SF, Chun FF, Recker F, Kwiatkowski M, 2014

    Journal: World J Urol
    Reference: Oct 31

  • 568. Family history in the finnish prostate cancer screening trial.

    Saarimäki L, Tammela TL, Määttänen L, Taari K, Kujala PM, Raitanen J, Auvinen A, 2015

    Journal: Int J Cancer.
    Reference: May 1;136(9):2172-7.

  • 567. Prostate cancer: Rescreening policies and risk calculators.

    Roobol MJ, 2014

    Journal: Nat Rev Urol.
    Reference: Aug;11(8):429-30.

Next →